Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Glide Pharma raises fresh investment to develop vaccine delivery system

Glide Pharma : 13 October, 2008  (Company News)
Glide Pharma has raised a fresh 2.2 million to help develop the Glide SDI - Solid Dose Injector.
Despite the harsh economic climate, existing investors, led by the Oxford Technology VCTs, were quick to respond and were joined by a handful of new investors in a fully subscribed fundraising.

The funding comes at a key stage in the company’s development as it targets the biologics injectables market which is forecast to grow to over $50 billion by 2012.

The Glide SDI is now in feasibility studies for delivering vaccines and biopharmaceuticals with five partners, three of which are new partners for 2008.

Commenting on the funding, Glide Pharma’s chief executive officer, Dr Charles Potter, said,: “This funding reflects the major progress we have made in positioning the Glide SDI system as a mainstream alternative for the injection of small molecules, biopharmaceuticals and vaccines. Our strategy has always been to seek funding from a position of strength and on a stage-by-stage basis. With five external funded studies underway in addition to our internal drug development programmes for octreotide and fentanyl, we feel confident in moving forward. Preliminary data from these studies, together with a vaccine feasibility study with the UK’s National Institute of Biological Standards and Control (NIBSC), is already extremely encouraging.”

Through a simple one-click action, the pen-like device of the Glide SDI pushes the solid dose, in the form of a tiny, pointed rod, through the skin where it subsequently dissolves to release the drug or vaccine to the body. This can provide key benefits to the patient, healthcare provider and manufacturer. Using a solid dose not only improves stability, but also avoids time-consuming reconstitution steps, and eliminates the risk of needle-stick injuries. In patient acceptance trials, participants have expressed a preference for the Glide SDI system over a traditional needle and syringe injection.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo